이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ESSA Pharma 관리

관리 기준 확인 4/4

ESSA Pharma's CEO는 David Parkinson, Jan2016 에 임명되었습니다 의 임기는 8.42 년입니다. 총 연간 보상은 $ 814.15K, 70.9% 로 구성됩니다. 70.9% 급여 및 29.1% 보너스(회사 주식 및 옵션 포함). 는 $ 306.46K 가치에 해당하는 회사 주식의 0.15% 직접 소유합니다. 306.46K. 경영진과 이사회의 평균 재임 기간은 각각 8.1 년과 5 년입니다.

주요 정보

David Parkinson

최고 경영자

US$814.2k

총 보상

CEO 급여 비율	70.9%
CEO 임기	8.5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	8.2yrs
이사회 평균 재임 기간	5.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

David Parkinson 의 보수는 ESSA Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	n/a	n/a	-US$26m
Sep 30 2023	US$814k	US$578k	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	n/a	n/a	-US$33m
Sep 30 2022	US$922k	US$549k	-US$35m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	n/a	n/a	-US$39m
Sep 30 2021	US$2m	US$518k	-US$37m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	n/a	n/a	-US$25m
Sep 30 2020	US$3m	US$492k	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	n/a	n/a	-US$15m
Sep 30 2019	US$996k	US$469k	-US$13m
Jun 30 2019	n/a	n/a	-US$12m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$1m	US$446k	-US$12m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	n/a	n/a	-US$8m
Sep 30 2017	US$964k	US$436k	-US$4m

보상 대 시장: David 의 총 보상 ($USD 814.15K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.62M ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Parkinson (74 yo)

8.5yrs

테뉴어

US$814,152

보상

Dr. David Ross Parkinson, M.D., has been a Director of Realm Therapeutics plc. since July 31, 2019. He serves as Member of Advisory Board at AsedaSciences Inc. Dr. Parkinson had been an Independent Directo...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Parkinson	President	8.5yrs	US$814.15k	0.15% $ 330.1k
David Wood	Chief Financial Officer	11yrs	US$590.39k	0.075% $ 167.4k
Peter Virsik	Executive VP & COO	7.9yrs	US$645.95k	0.025% $ 56.5k
Alessandra Cesano	Chief Medical Officer & Executive VP	5yrs	US$623.93k	0.012% $ 25.7k
Chandtip Chandhasin	Executive	no data	데이터 없음	데이터 없음
Erica Osbourne	Executive	no data	데이터 없음	데이터 없음
Erin Rudsinski	Executive	no data	데이터 없음	데이터 없음
Loleta Harris	Executive	no data	데이터 없음	데이터 없음
Neil Thapar	Executive	no data	데이터 없음	데이터 없음
Nkengyal Barber	Executive	no data	데이터 없음	데이터 없음
Steve Pondell	Executive	no data	데이터 없음	데이터 없음
Terry Schuenemeyer	Executive	no data	데이터 없음	데이터 없음

8.2yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: EPIX 의 관리팀은 노련하고 경험 (평균 재직 기간 8.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Parkinson	President	9.1yrs	US$814.15k	0.15% $ 330.1k
Sanford Zweifach	Independent Director	5yrs	US$48.00k	0% $ 0
Richard Glickman	Independent Chairman of the Board	13.8yrs	US$70.00k	0.097% $ 217.1k
Gary Sollis	Independent Director	12.3yrs	US$50.00k	0% $ 0
John Martin	Independent Director	5yrs	US$35.00k	0.032% $ 71.8k
Franklin Berger	Independent Director	9.3yrs	US$54.00k	1.77% $ 3.9m
Scott Requadt	Independent Director	8.5yrs	US$47.00k	0.068% $ 150.6k
Philip Kantoff	Independent Director	1.8yrs	US$35.00k	0% $ 0
Marella Thorell	Independent Director	5yrs	US$42.00k	0.0065% $ 14.5k
Marianne Sadar	Scientific Advisor	5.1yrs	US$229.20k	데이터 없음
Raymond Andersen	Scientific Advisor	no data	US$229.20k	데이터 없음
Lauren Merendino	Independent Director	1.1yrs	US$162.67k	0% $ 0

5.1yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: EPIX 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

ESSA Pharma 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

Independent Director recently bought US$135k worth of stock

Independent Director recently bought US$420k worth of stock

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Independent Director notifies of intention to sell stock

Recent updates

New major risk - Revenue and earnings growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

New major risk - Revenue and earnings growth

Independent Director recently bought US$135k worth of stock

New major risk - Share price stability

Independent Director recently bought US$420k worth of stock

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Now 21% undervalued after recent price drop

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Now 23% undervalued

Independent Director notifies of intention to sell stock

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2023

ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen

Insufficient new directors

ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Appoints Philip Kantoff to its Board of Directors

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

ESSA Pharma Inc. Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients

ESSA Pharma Inc. Enters into Clinical Collaboration and Supply Agreement with Astellas Pharma Inc. to Evaluate Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. has completed a Follow-on Equity Offering in the amount of $130.434786 million.

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

ESSA Pharma EPS beats by $0.02

ESSA Pharma Inc. Announces Voluntary Delisting from the TSX-V

New 90-day low: US$6.10

Independent Chairman of the Board recently bought US$37k worth of stock

Essa Pharma Inc. Announces the Presentation of Data of ESSA's Clinical Candidate, EPI-7386, at the ESMO Virtual Congress 2020

New 90-day high - US$7.64

Independent Director recently bought US$551k worth of stock

New 90-day high - US$7.06

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령